• BMS 309403: From FABP4 Biology to Translation

  2026-08-13

  FABP4 is increasingly understood as a signaling node linking fatty acid handling, macrophage inflammation, foam cell formation, and metabolic dysfunction. This thought-leadership article interprets recent SERCA2–calcineurin–FoxO1–FABP4 findings through a translational lens and positions BMS 309403 as a selective pharmacological tool for testing pathway causality. It also outlines experimental controls, workflow parameters, model-selection logic, and the limitations researchers should address before connecting mechanistic observations to therapeutic hypotheses.

• Structural Insights into CD38 CAR Affinity Tuning

  2026-08-13

  The iScience study dissects how the CD38 CAR binders RP02 and 028 recognize distinct antigen surfaces and alter CD38 enzymatic function. Its combination of structural analysis, alanine scanning, and CAR-T testing shows how affinity attenuation can reduce fratricide while preserving antitumor cytotoxicity.

• O-propargyl-puromycin (OPP) in B-Cell Assays

  2026-08-12

  O-propargyl-puromycin (OPP) converts a short translation pulse into a measurable signal for comparing protein synthesis across B-cell states, mitochondrial perturbations, and immune responses. This workflow combines quantitative nascent-polypeptide labeling with click chemistry, enabling microscopy, flow cytometry, or proteomics-oriented analysis.

• H-89: Testing the PKA-Metabolism Axis in Osteogenesis

  2026-08-12

  Wnt-driven bone formation is increasingly understood as a signaling-to-metabolism problem. This thought-leadership article examines how H-89, a cAMP-dependent protein kinase inhibitor, can help translational researchers test the Ca2+-PKA-GFAT1-O-GlcNAcylation axis described in recent osteogenesis research. It also outlines experimental safeguards, competitive advantages, translational boundaries, and a practical path from pathway perturbation to mechanistic confidence.

• 4-Ethylphenyl Sulfate: Assay Context Matters

  2026-08-11

  4-Ethylphenyl sulfate is a microbiota-derived uremic toxin relevant to renal and neurobehavioral research. This guide explains how chemical properties, biological matrices, and surface adsorption can determine whether an assay result reflects biology or experimental context.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-08-10

  Blommel and Blommel’s clinical review examines dabigatran etexilate as an orally administered, reversible direct thrombin inhibitor designed to overcome important limitations of warfarin and injectable anticoagulants. Its prodrug activation, predictable pharmacokinetics, clinical efficacy, renal dependence, and interaction profile provide a useful framework for interpreting modern anticoagulant pharmacotherapy and drug-drug interaction research.

• 4-Hydroxytamoxifen: Practical DMSO Workflow

  2026-08-09

  4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled cell, cardiac myocyte, and selected mouse-model workflows. It is appropriate for studies designed around DMSO delivery, but should not be selected for protocols requiring water- or ethanol-based preparation, and solution storage should be minimized.

• Thiothixene: Macrophage Efferocytosis Workflows

  2026-08-08

  Thiothixene is a typical antipsychotic agent with a useful research profile that connects dopamine receptor biology to macrophage efferocytosis. This guide translates its Stra6l–vitamin A signaling activity and pharmacokinetic evidence into practical assay design, controls, and troubleshooting decisions.

• 2-Thio-dCTP for Chromatin Assay Design

  2026-08-07

  Discover how 2-Thio-dCTP and 2-Thio-2'-deoxycytidine-5'-Triphosphate can improve DNA-centered assay design without confusing nucleotide modification with histone phosphorylation biology. This guide connects sulfur-modified DNA chemistry with practical studies of DNA-protein interactions, polymerase selectivity, and chromosome stability.

• Dual-Action p38α Inhibitors Stimulate Dephosphorylation: New

  2026-08-07

  The reference study reveals that certain p38α MAPK inhibitors not only block kinase activity but also promote dephosphorylation by stabilizing a phosphatase-accessible conformation. This dual-action mechanism suggests new strategies for achieving greater specificity in MAPK-targeted research and has direct implications for inflammation and cytokine signaling studies.

• Reliable GLI Inhibition in Cancer Research Using GANT61 (A16

  2026-08-06

  This article delivers an evidence-based, scenario-driven guide for deploying GANT61 (SKU A1615) as a selective GLI inhibitor in cancer research. Drawing on validated protocols and recent scientific findings, it addresses common laboratory challenges in cell-based assays, highlights GLI-mediated transcription inhibition, and benchmarks GANT61’s performance and reliability for translational workflows.

• Host-Directed Targets in Macrophage Killing of Gram-Positive

  2026-08-06

  Russell et al. employ a pathogen-centric approach to reveal how immune-adaptive variation in Streptococcus pneumoniae identifies host factors—namely ACOD1/itaconate, NAMPT, and P2RX7—as critical mediators of macrophage microbicidal activity. These findings present new avenues for host-directed therapies that may overcome antimicrobial resistance.

• ALDH2 Inhibition Drives Synthetic Lethality in APC-Deficient

  2026-08-05

  Liang et al. demonstrate that ALDH2 inhibition—using the dopamine β-hydroxylase inhibitor Disulfiram—induces synthetic lethality in APC-deficient colorectal cancer through the ROS/ASK1/JNK pathway. This mechanistic insight offers a targeted therapeutic strategy for a high-mutation CRC subtype.

• 10058-F4: Selective c-Myc-Max Dimerization Inhibitor for Can

  2026-08-05

  10058-F4 is a well-characterized c-Myc-Max dimerization inhibitor that disrupts oncogenic transcriptional activity. Its efficacy in acute myeloid leukemia and prostate cancer xenograft models is supported by both in vitro and in vivo data. Optimized protocols and clear solubility parameters enable reproducible results for apoptosis and cell cycle studies.

• Rucaparib (AG-014699): Spliceosome, DNA Repair, and Radiosen

  2026-08-04

  Explore the evolving landscape of PARP inhibitor research with a focus on Rucaparib (AG-014699) and its intersection with spliceosome regulation and radiosensitization in cancer models. This thought-leadership article connects mechanistic insight with actionable guidance for translational researchers, leveraging the latest findings on SmD2 acetylation and integrating protocol advice for robust DNA repair studies.

450 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page